NCT04091854

The Progress of Diabetes Mellitus After HMS5552 Treatment in Type 2 Diabetes Mellitus

A Study to Observe the Progress of Diabetes Mellitus After 52 or 28 Weeks of HMS5552 Treatment for Type 2 Diabetes Mellitus

• Status: Unknown
• Phase: —
• Study type: Observational
• Enrollment: 24 (actual)
• Sponsor: Majianhua · Academic / Other
• Sex: All
• Age: 18 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

At present, there are few studies on the clinical remission rate of diabetes after one year discontinuation of oral hypoglycemic drugs after intensive treatment. HMS5552 is a kind of GKA hypoglycemic drug. This study intends to observe the clinical remission rate of diabetes mellitus, beta cell function and blood sugar fluctuation of patients with type 2 diabetes mellitus who have been treated with HMS5552 for 52W or 28W and whose glucose control is up to the standard.

Conditions

• Type2 Diabetes Mellitus

Interventions

Type	Name	Description
DRUG	HMS5552	To observe the progress of diabetes mellitus after 52 or 28 weeks of HMS5552 treatment for type 2 diabetes mellitus

Timeline

• Start date: 2018-12-12
• Primary completion: 2022-03-01
• Completion: 2022-03-01
• First posted: 2019-09-17
• Last updated: 2021-08-26

Locations

1 site across 1 country: China